Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking approach to diabetes management. These innovative drugs operate by mimicking the inherent actions of GLP-1, a hormone produced by the gut in response to meals. By stimulating GLP-1 receptors in the pancreas, these agents enhance insulin secretion and suppress glucagon o

The burgeoning landscape of novel treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting significant weight decrease – they exhibit intriguing differences in their